Receive Groundbreaking Mammary Carcinoma Research

image000001 (1) (1)

We will share the newest research on mammary carcinoma with you as soon as it's widely available. (after ESVONC)

While you wait, we encourage you to read about a real-life mammary carcinoma case study featuring Missy.  After one year of FidoCure® targeted therapy, Missy showed no evidence of pulmonary metastatic disease.

Send me the research

Mammary Carcinoma Data from the FidoCure Fetch Platform

Media Survival Time from DX: 327 Days

Cases: 127 Patients

newplot (11)
newplot (10)

DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy. 

© Copyright 2018-2022 OHC, All rights reserved